Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozekibart, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obertamig, an antibody targeting CD3E × HLA-G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lipustobart, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epacmarstobart, an antibody targeting SIRPA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciduvectamig, an antibody targeting TMEFF2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Uprevstobart, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solrikitug, an antibody targeting TSLP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Samatatug, an antibody targeting Tissue factor.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rezetamig, an antibody targeting CD3 × CD22.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opelkibart, an antibody targeting KIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Linclatamig, an antibody targeting LY6G6D × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enristomig, an antibody targeting PD-L1 × 4-1BB.